Research programme: Tau dysfunction regulators - Bristol-Myers Squib/Gladstone Institutes
Latest Information Update: 16 Jul 2016
At a glance
- Originator Bristol-Myers Squibb; The J. David Gladstone Institutes
- Class
- Mechanism of Action Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 27 Dec 2011 Early research in Alzheimer's disease in USA (unspecified route)